샘플 요청 목록

 카트 문의
시장보고서
상품코드
1788251

세계의 PARP 저해제 바이오마커 시장

PARP Inhibitor Biomarkers
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 278 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 PARP 저해제 바이오마커 시장은 2030년까지 15억 달러에 도달

2024년에 9억 5,170만 달러로 추정된 세계의 PARP 저해제 바이오마커 시장은 분석 기간인 2024-2030년에 CAGR 7.6%로 성장하며, 2030년에는 15억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 PARP 저해제 바이오마커 키트는 CAGR 8.8%를 기록하며, 분석 기간 종료까지 10억 달러에 달할 것으로 예측됩니다. PARP 저해제 바이오마커 어세이 분야의 성장률은 분석 기간 중 CAGR 5.3%로 추정됩니다.

미국 시장은 2억 5,930만 달러, 중국은 CAGR 12.1%로 성장할 것으로 예측

미국의 PARP 저해제 바이오마커 시장은 2024년에는 2억 5,930만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 12.1%로, 2030년까지 3억 1,740만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.7%와 7.4%로 예측됩니다. 유럽에서는 독일이 CAGR 5.1%로 성장할 것으로 예측됩니다.

세계의 PARP 저해제 바이오마커 시장 - 주요 동향과 촉진요인 정리

PARP 억제제 바이오마커 시장 성장의 이유는 무엇인가?

PARP 억제제 바이오마커 시장은 암 영역에서 정밀의료의 역할이 커짐에 따라 확대되고 있습니다. PARP(폴리 ADP 리보스 중합효소) 억제제는 난소암, 유방암, 전립선암, 췌장암 등의 치료에 사용되는 표적치료제의 일종입니다. PARP 억제제에 반응하는 환자를 식별하기 위한 예측 바이오마커의 필요성이 동반진단 및 게놈 검사의 발전을 촉진하고 있습니다.

또한 차세대 염기서열 분석(NGS) 및 액체생검 기술의 활용도가 높아짐에 따라 보다 정확한 바이오마커 식별이 가능해짐에 따라 치료 선택과 환자 예후가 개선되고 있습니다. PARP 억제제의 새로운 응용을 모색하는 임상시험의 확대는 시장 수요를 더욱 촉진하고 있습니다.

게놈 검사와 동반 진단은 PARP 억제제 바이오마커 식별을 어떻게 변화시키고 있는가?

게놈 검사의 암 치료로의 통합은 PARP 억제제 바이오마커 탐색에 혁명을 일으키고 있습니다. BRCA1/2 돌연변이 검사, 상동결합결손(HRD) 분석, 헤테로 접합체 결손(LOH) 분석은 PARP 억제제의 효과를 예측하기 위한 표준 검사로 자리잡아가고 있습니다. 이러한 바이오마커는 종양 전문의가 치료 계획을 조정하고 치료 성공률을 높이는 데 도움이 됩니다.

동반 진단도 중요한 역할을 하고 있으며, 규제기관은 PARP 억제제 치료와 동시에 바이오마커에 기반한 검사를 승인하고 있습니다. AI 기반 바이오인포매틱스 툴은 바이오마커 식별을 더욱 정교하게 만들어 정확성과 임상적 의사결정을 향상시키고 있습니다.

PARP 억제제의 적용 확대가 시장 성장을 가속하는가?

난소암, 유방암 외에도 PARP 억제제의 적용이 확대되고 있는 것이 PARP 억제제 바이오마커 시장을 확대하고 있습니다. 폐암, 췌장암, 대장암에 대한 사용이 검토되고 있으며, 환자 선택에 대한 가이드라인이 될 수 있는 바이오마커 검사에 대한 수요가 증가하고 있습니다.

또한 PARP 억제제와 면역관문억제제를 포함한 병용요법의 등장은 바이오마커 혁신의 원동력이 되고 있습니다. 과학자들은 종양의 미세 환경과 면역 반응을 평가하는 예측 검사를 개발하여 보다 개인화된 치료 전략으로 연결하고 있습니다.

PARP 억제제 바이오마커 시장의 성장 원동력은?

PARP 억제제 바이오마커 시장의 성장은 정밀 종양학의 채택 증가, 게놈 검사의 발전, PARP 억제제의 적용 확대에 의해 이루어질 것입니다. 동반진단 및 AI를 활용한 바이오마커 식별에 대한 수요 증가는 시장 성장을 더욱 가속화하고 있습니다.

또한 바이오마커 기반 치료에 대한 규제 당국의 승인, 암 연구에 대한 투자 증가, NGS와 액체생검 기술의 통합이 기술 혁신을 촉진하고 있습니다. 맞춤 암 치료가 계속 발전함에 따라 PARP 억제제 바이오마커에 대한 수요는 크게 증가할 것으로 예측됩니다.

부문

제품 유형(PARP 저해제 바이오마커 키트, PARP 저해제 바이오마커 어세이); 애플리케이션(유방암 애플리케이션, 난소암 애플리케이션, 기타 애플리케이션)

조사 대상 기업의 예

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • AstraZeneca
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • GlaxoSmithKline(GSK)
  • Illumina, Inc.
  • Invitae Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Pfizer Inc.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.18

Global PARP Inhibitor Biomarkers Market to Reach US$1.5 Billion by 2030

The global market for PARP Inhibitor Biomarkers estimated at US$951.7 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PARP Inhibitor Biomarker Kits, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the PARP Inhibitor Biomarker Assays segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$259.3 Million While China is Forecast to Grow at 12.1% CAGR

The PARP Inhibitor Biomarkers market in the U.S. is estimated at US$259.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$317.4 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global PARP Inhibitor Biomarkers Market - Key Trends & Drivers Summarized

Why Is the PARP Inhibitor Biomarkers Market Gaining Momentum?

The PARP inhibitor biomarkers market is expanding as the role of precision medicine in oncology continues to grow. PARP (poly ADP-ribose polymerase) inhibitors are a class of targeted therapies used in the treatment of cancers such as ovarian, breast, prostate, and pancreatic cancer. The need for predictive biomarkers to identify patients who will respond to PARP inhibitors is driving advancements in companion diagnostics and genomic testing.

Additionally, the increasing availability of next-generation sequencing (NGS) and liquid biopsy technologies is enabling more precise biomarker identification, improving treatment selection and patient outcomes. The expansion of clinical trials exploring new applications of PARP inhibitors is further fueling market demand.

How Are Genomic Testing and Companion Diagnostics Transforming PARP Inhibitor Biomarker Identification?

The integration of genomic testing into cancer care is revolutionizing PARP inhibitor biomarker discovery. BRCA1/2 mutation testing, homologous recombination deficiency (HRD) assays, and loss-of-heterozygosity (LOH) analysis are becoming standard tests for predicting PARP inhibitor efficacy. These biomarkers help oncologists tailor treatment plans, improving therapeutic success rates.

Companion diagnostics are also playing a crucial role, with regulatory agencies approving biomarker-based tests alongside PARP inhibitor therapies. AI-driven bioinformatics tools are further refining biomarker identification, enhancing accuracy and clinical decision-making.

Is the Expansion of PARP Inhibitor Applications Driving Market Growth?

The growing application of PARP inhibitors beyond ovarian and breast cancer is expanding the market for PARP inhibitor biomarkers. Research is exploring their use in lung, pancreatic, and colorectal cancers, increasing the demand for biomarker testing to guide patient selection.

Additionally, the rise of combination therapies involving PARP inhibitors and immune checkpoint inhibitors is driving biomarker innovation. Scientists are developing predictive tests that assess tumor microenvironments and immune response, leading to more personalized treatment strategies.

What’s Driving the Growth of the PARP Inhibitor Biomarkers Market?

The growth in the PARP inhibitor biomarkers market is driven by the increasing adoption of precision oncology, advancements in genomic testing, and the expansion of PARP inhibitor applications. The rising demand for companion diagnostics and AI-powered biomarker identification is further accelerating market growth.

Additionally, regulatory approvals for biomarker-driven therapies, the growing investment in cancer research, and the integration of NGS and liquid biopsy technologies are fueling innovation. As personalized cancer treatment continues to evolve, the demand for PARP inhibitor biomarkers is expected to rise significantly.

SCOPE OF STUDY:

The report analyzes the PARP Inhibitor Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (PARP Inhibitor Biomarker Kits, PARP Inhibitor Biomarker Assays); Application (Breast Cancer Application, Ovarian Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • AstraZeneca
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • GlaxoSmithKline (GSK)
  • Illumina, Inc.
  • Invitae Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Pfizer Inc.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • PARP Inhibitor Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Precision Oncology Throw Spotlight on Biomarker-Guided PARP Inhibitor Therapies
    • Growing Clinical Validation of BRCA and HRD Biomarkers Accelerates Diagnostic Adoption
    • FDA Approvals and Expanded Indications Propel Growth in Companion Diagnostics
    • Increasing Use of Genomic Testing in Ovarian, Breast, and Prostate Cancer Supports Market Expansion
    • Rising Investment in Targeted Cancer Therapies Strengthens Business Case for Biomarker Discovery
    • Integration of Next-Generation Sequencing Enhances Detection Accuracy and Clinical Utility
    • Reimbursement Expansion for Molecular Diagnostic Panels Drives Adoption in Oncology Workflows
    • Strategic Collaborations Between Pharma and Diagnostic Firms Accelerate Commercialization
    • Growing Role of Tumor Profiling in Therapy Selection Expands Demand for Companion Biomarkers
    • Emergence of Liquid Biopsy-Based Assays Opens Up Non-Invasive Testing Opportunities
    • Academic Research and Clinical Trials Fuel Development of Novel Predictive Biomarkers
    • Global Push for Personalized Cancer Care Supports Inclusion of PARP Biomarkers in Guidelines
    • Integration with AI and Data Analytics Tools Improves Biomarker Interpretation and Treatment Decisions
    • Pharmaceutical Pipeline Expansion of PARP Inhibitors Creates Parallel Demand for Diagnostic Ecosystem
    • Regulatory Harmonization in Biomarker Validation Enhances Global Market Accessibility
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PARP Inhibitor Biomarkers Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for PARP Inhibitor Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarker Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for PARP Inhibitor Biomarker Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for PARP Inhibitor Biomarker Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarker Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for PARP Inhibitor Biomarker Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for PARP Inhibitor Biomarker Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ovarian Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ovarian Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Ovarian Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for PARP Inhibitor Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제